Allogeneic Natural Killer (NK) Cells for Oncology
Natural Killer (NK) cells are essential components of the immune system, playing an important role in the body’s defensive response against tumors and infected cells. NK cells constantly patrol the body to detect and neutralize foreign cells. Senti Bio believes there are several advantages that NK cells confer in relation to other potential immune cell types in oncology: innate killing, immune activation, previously validated efficacy and safety, and broad patient access since they may be delivered rapidly to patients in an off-the-shelf manner and in outpatient settings.
We are Building Manufacturing Capabilities to Enable Production of Off-The-Shelf Cell Therapies
Internal manufacturing capabilities are central to our business strategy, since they can enable us to control the quality and supply of our allogeneic CAR-NK cell therapies for clinical studies and ultimately commercialization. A key advantage of allogeneic cell therapies, versus autologous products that use each patient’s own cells, is the ability to manufacture large batches of drug product from healthy donor cells that can be produced in advance of clinical use, and then stored in frozen vials. Upon commercialization, we expect to be able to make our cell therapies, if approved, can be made broadly accessible in an off-the-shelf manner to cancer patients.